JP2011092201A5 - - Google Patents

Download PDF

Info

Publication number
JP2011092201A5
JP2011092201A5 JP2010286755A JP2010286755A JP2011092201A5 JP 2011092201 A5 JP2011092201 A5 JP 2011092201A5 JP 2010286755 A JP2010286755 A JP 2010286755A JP 2010286755 A JP2010286755 A JP 2010286755A JP 2011092201 A5 JP2011092201 A5 JP 2011092201A5
Authority
JP
Japan
Prior art keywords
compound according
compound
oligonucleotide
inhibiting
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010286755A
Other languages
English (en)
Japanese (ja)
Other versions
JP5923241B2 (ja
JP2011092201A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011092201A publication Critical patent/JP2011092201A/ja
Publication of JP2011092201A5 publication Critical patent/JP2011092201A5/ja
Application granted granted Critical
Publication of JP5923241B2 publication Critical patent/JP5923241B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2010286755A 2003-09-09 2010-12-22 テロメラーゼ阻害のための改変オリゴヌクレオチド Expired - Lifetime JP5923241B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50150903P 2003-09-09 2003-09-09
US60/501,509 2003-09-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006526347A Division JP4690324B2 (ja) 2003-09-09 2004-09-09 テロメラーゼ阻害のための改変オリゴヌクレオチド

Related Child Applications (3)

Application Number Title Priority Date Filing Date
JP2011274595A Division JP2012085648A (ja) 2003-09-09 2011-12-15 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2014087190A Division JP2014158490A (ja) 2003-09-09 2014-04-21 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2016014128A Division JP6158966B2 (ja) 2003-09-09 2016-01-28 テロメラーゼ阻害のための改変オリゴヌクレオチド

Publications (3)

Publication Number Publication Date
JP2011092201A JP2011092201A (ja) 2011-05-12
JP2011092201A5 true JP2011092201A5 (cg-RX-API-DMAC7.html) 2012-02-16
JP5923241B2 JP5923241B2 (ja) 2016-05-24

Family

ID=34273050

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2006526347A Expired - Lifetime JP4690324B2 (ja) 2003-09-09 2004-09-09 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2010286755A Expired - Lifetime JP5923241B2 (ja) 2003-09-09 2010-12-22 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2011274595A Pending JP2012085648A (ja) 2003-09-09 2011-12-15 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2014087190A Pending JP2014158490A (ja) 2003-09-09 2014-04-21 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2016014128A Expired - Lifetime JP6158966B2 (ja) 2003-09-09 2016-01-28 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2016137263A Withdrawn JP2016214248A (ja) 2003-09-09 2016-07-12 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2018025362A Expired - Lifetime JP6758335B2 (ja) 2003-09-09 2018-02-15 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2019131757A Withdrawn JP2019170400A (ja) 2003-09-09 2019-07-17 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2021110558A Withdrawn JP2021169466A (ja) 2003-09-09 2021-07-02 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2023086871A Withdrawn JP2023099808A (ja) 2003-09-09 2023-05-26 テロメラーゼ阻害のための改変オリゴヌクレオチド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006526347A Expired - Lifetime JP4690324B2 (ja) 2003-09-09 2004-09-09 テロメラーゼ阻害のための改変オリゴヌクレオチド

Family Applications After (8)

Application Number Title Priority Date Filing Date
JP2011274595A Pending JP2012085648A (ja) 2003-09-09 2011-12-15 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2014087190A Pending JP2014158490A (ja) 2003-09-09 2014-04-21 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2016014128A Expired - Lifetime JP6158966B2 (ja) 2003-09-09 2016-01-28 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2016137263A Withdrawn JP2016214248A (ja) 2003-09-09 2016-07-12 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2018025362A Expired - Lifetime JP6758335B2 (ja) 2003-09-09 2018-02-15 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2019131757A Withdrawn JP2019170400A (ja) 2003-09-09 2019-07-17 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2021110558A Withdrawn JP2021169466A (ja) 2003-09-09 2021-07-02 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2023086871A Withdrawn JP2023099808A (ja) 2003-09-09 2023-05-26 テロメラーゼ阻害のための改変オリゴヌクレオチド

Country Status (19)

Country Link
US (8) US7494982B2 (cg-RX-API-DMAC7.html)
EP (3) EP3342425B1 (cg-RX-API-DMAC7.html)
JP (10) JP4690324B2 (cg-RX-API-DMAC7.html)
KR (3) KR101298493B1 (cg-RX-API-DMAC7.html)
CN (2) CN100393209C (cg-RX-API-DMAC7.html)
AU (2) AU2004271215B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414222B8 (cg-RX-API-DMAC7.html)
CA (1) CA2536015C (cg-RX-API-DMAC7.html)
CY (2) CY1120113T1 (cg-RX-API-DMAC7.html)
DK (2) DK3342425T3 (cg-RX-API-DMAC7.html)
ES (2) ES2662196T3 (cg-RX-API-DMAC7.html)
HU (2) HUE048359T2 (cg-RX-API-DMAC7.html)
IL (1) IL173747A (cg-RX-API-DMAC7.html)
MX (1) MXPA06002660A (cg-RX-API-DMAC7.html)
NZ (1) NZ545516A (cg-RX-API-DMAC7.html)
PL (2) PL1667522T3 (cg-RX-API-DMAC7.html)
PT (2) PT3342425T (cg-RX-API-DMAC7.html)
SI (2) SI3342425T1 (cg-RX-API-DMAC7.html)
WO (1) WO2005023994A2 (cg-RX-API-DMAC7.html)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2662196T3 (es) * 2003-09-09 2018-04-05 Geron Corporation Oligonucleótidos modificados para la inhibición de la telomerasa
EP1694842B1 (en) 2003-11-04 2011-03-23 Geron Corporation Rna amidates and thioamidates for rnai
PT3296312T (pt) 2004-07-02 2021-05-11 Geron Corp Síntese de monómeros nucleosídeos 3'-amino 5'-fosforamidite protegidos
WO2006113470A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
US8252756B2 (en) 2005-06-14 2012-08-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
WO2007127163A2 (en) * 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
EP2101789B1 (en) 2006-10-30 2014-12-31 Geron Corporation Combined telomerase inhibitor and gemcitabine for the treatment of cancer
WO2008094640A2 (en) 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells
AU2008212820B2 (en) 2007-02-09 2014-01-30 Northwestern University Particles for detecting intracellular targets
US9155753B2 (en) * 2007-03-09 2015-10-13 Geron Corporation Treatment of carcinomas with a combination of EGF-pathway and telomerase inhibitors
HUE028389T2 (en) 2007-05-10 2016-12-28 Agilent Technologies Inc For the synthesis of thiocarbons protecting groups RNSS
DK2160464T3 (da) 2007-05-30 2014-08-04 Univ Northwestern Nukleinsyrefunktionaliserede nanopartikler til terapeutiske anvendelser
TW200927177A (en) * 2007-10-24 2009-07-01 Nat Inst Of Advanced Ind Scien Lipid-modified double-stranded RNA having potent RNA interference effect
US8440809B2 (en) * 2008-07-02 2013-05-14 Santaris Pharma A/S RNA antagonists targeting Hsp27
EP2175023A1 (en) * 2008-07-31 2010-04-14 The University of Zurich Anti-tumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA
DK2342360T3 (en) 2008-10-17 2016-04-11 Geron Corp Method for identification of sensitivity of a patient to telomerase inhibition therapy
WO2010060110A1 (en) 2008-11-24 2010-05-27 Northwestern University Polyvalent rna-nanoparticle compositions
AU2009323766B2 (en) 2008-12-02 2016-10-06 Wave Life Sciences Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
SG177564A1 (en) 2009-07-06 2012-02-28 Ontorii Inc Novel nucleic acid prodrugs and methods of use thereof
WO2011053940A2 (en) 2009-10-30 2011-05-05 Northwestern University Templated nanoconjugates
US20130178610A1 (en) * 2009-12-24 2013-07-11 Chad A. Mirkin Oligonucleotide specific uptake of nanoconjugates
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
WO2012135125A1 (en) 2011-03-28 2012-10-04 Geron Corporation Telomere length measurement in formalin-fixed, paraffin embedded (ffpe) samples by quantitative pcr
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
US9889209B2 (en) 2011-09-14 2018-02-13 Northwestern University Nanoconjugates able to cross the blood-brain barrier
JP6268157B2 (ja) 2012-07-13 2018-01-24 株式会社Wave Life Sciences Japan 不斉補助基
SG10201912895PA (en) 2012-07-13 2020-02-27 Wave Life Sciences Ltd Chiral control
US9228189B2 (en) 2012-10-26 2016-01-05 Geron Corporation C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
CA3201145A1 (en) 2012-10-26 2014-05-01 Geron Corporation C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
SI3495495T1 (sl) 2012-11-30 2021-07-30 Geron Corporation Diagnostični markerji za zdravljenje celičnih proliferativnih motenj s telomeraznimi inhibitorji
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
PL3646876T3 (pl) 2012-12-07 2024-07-22 Geron Corporation Inhibitor telomerazy, imetelstat do leczenia zaburzeń mieloproliferacyjnych i nowotworów mieloproliferacyjnych
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
ES3047667T3 (en) 2013-02-22 2025-12-04 Univ Leland Stanford Junior Methods relating to telomere extension
AU2014292926B2 (en) 2013-07-25 2020-03-05 Exicure Operating Company Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
EP3052512A4 (en) 2013-09-30 2017-02-22 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
PT3094728T (pt) 2014-01-16 2022-05-19 Wave Life Sciences Ltd Desenho quiral
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
CN107427592A (zh) * 2015-01-05 2017-12-01 株式会社露太利温 使用luterion抑制癌细胞中端粒酶的方法
CA2978191C (en) * 2015-04-23 2022-10-04 Geron Corporation Methods of polynucleotide preparation using multivalent cation salt compositions
EP3124609A1 (en) 2015-07-29 2017-02-01 IFOM Fondazione Istituto Firc di Oncologia Molecolare Therapeutics oligonucleotides
EP3650546A1 (en) 2015-07-29 2020-05-13 IFOM Fondazione Istituto Firc di Oncologia Molecolare Therapeutic oligonucleotides
MA45290A (fr) * 2016-05-04 2019-03-13 Wave Life Sciences Ltd Procédés et compositions d'agents biologiquement actifs
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
KR20250038815A (ko) * 2017-04-20 2025-03-19 신테나 아게 트리시클로-dna 뉴클레오시드를 포함하는 변형 올리고머 화합물 및 그의 용도
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
ES2901099T3 (es) * 2017-07-10 2022-03-21 Geron Corp Proceso mejorado para la preparación de imetelstat
TWI879717B (zh) 2017-07-28 2025-04-11 美商傑龍公司 治療骨髓增生不良症候群之方法
TW202016301A (zh) 2018-05-07 2020-05-01 美商阿里拉姆製藥股份有限公司 肝外遞送技術
CA3120704A1 (en) 2018-11-29 2020-06-04 Geron Corporation Methods of treating myelodysplastic syndrome
WO2021054370A1 (ja) * 2019-09-18 2021-03-25 国立大学法人東京医科歯科大学 核酸複合体
CN114901269A (zh) * 2019-10-28 2022-08-12 美国杰龙生物医药公司 3-棕榈酰基-酰胺基-1,2-丙二醇和3-棕榈酰基-酰胺基-2-羟基-1-二甲氧基三苯基甲基醚-丙烷的结晶固体及其制备和使用方法
KR102861357B1 (ko) 2019-10-28 2025-09-18 제론 코포레이션 비정질 고체 석신일화 3-(지방산 아미도)-2-하이드록시-1-(보호된 하이드록시)-프로판 염 및 이를 제조하는 방법
AU2021309963A1 (en) 2020-07-17 2023-02-02 Geron Corporation Subcutaneous telomerase inhibitor compositions and methods for using same
WO2022186350A1 (ja) * 2021-03-03 2022-09-09 国立大学法人東京大学 非環式スレオニノール核酸
EP4463151A4 (en) 2022-01-19 2025-10-01 Univ Northwestern Agents Targeting Telomerase Reverse Transcriptase (TERT) to Treat Cancer and Sensitize Cancer Cells to Genotoxic Therapy
WO2024257861A1 (ja) * 2023-06-16 2024-12-19 日産化学株式会社 脂質結合オリゴヌクレオチド又はその複合体

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US6448392B1 (en) * 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4757141A (en) * 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
DK0462145T3 (da) * 1989-03-07 1994-08-08 Genentech Inc Covalente konjugater mellem lipid og oligonucleotid
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US6153737A (en) * 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6114513A (en) * 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
US6395492B1 (en) * 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
WO1991014696A1 (en) * 1990-03-29 1991-10-03 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5420330A (en) 1990-09-07 1995-05-30 Pharmacia P-L Biochemicals Inc. Lipo-phosphoramidites
US5419966A (en) * 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5837453A (en) 1992-05-13 1998-11-17 Geron Corporation Telomerase activity assays
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US6235886B1 (en) * 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
IL107150A0 (en) * 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
US7067497B2 (en) * 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US6350853B1 (en) * 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
DE4331670A1 (de) * 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
JP4281926B2 (ja) * 1993-10-18 2009-06-17 ザ・ワルター・アンド・エリザ・ホール・インスティテュート・オヴ・メディカル・リサーチ ニューロンの生き残りを増加させる方法およびそれに有用な薬剤
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
JP3482209B2 (ja) 1994-03-18 2003-12-22 ジェロン・コーポレーション オリゴヌクレオチドn3’→p5’ホスホルアミデート:合成および化合物;ハイブリダイゼーションおよびヌクレアーゼ耐性特性
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
GB9413035D0 (en) * 1994-06-29 1994-08-17 Scras Antisense oligonucleeotides
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
CN1231491C (zh) 1994-07-07 2005-12-14 杰龙公司 哺乳动物端粒酶
JPH10509447A (ja) 1994-11-07 1998-09-14 ハイブライドン インコーポレイテッド 3h−1,2−ベンゾジチオール−3−1,1−ジオキシドを用いた▲上35▼s−標識オリゴヌクレオチドの合成
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
GB9606158D0 (en) 1996-03-23 1996-05-29 Ciba Geigy Ag Chemical compounds
US6015710A (en) * 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
AU2445997A (en) * 1996-04-10 1997-10-29 Lynx Therapeutics, Inc. Telomerase inhibitors
US6111085A (en) * 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6001991A (en) * 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US5846723A (en) * 1996-12-20 1998-12-08 Geron Corporation Methods for detecting the RNA component of telomerase
AU733610B2 (en) 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
JP3722630B2 (ja) 1998-10-28 2005-11-30 パイオニア株式会社 記録再生装置
US6656730B1 (en) * 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
JP4267233B2 (ja) 1999-09-10 2009-05-27 ジェロン・コーポレーション オリゴヌクレオチドn3’→p5’チオホスホルアミデート:それらの合成および使用
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
JP4854913B2 (ja) 2001-03-23 2012-01-18 ジェロン・コーポレーション オリゴヌクレオチド結合体
US7563618B2 (en) * 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
ES2662196T3 (es) 2003-09-09 2018-04-05 Geron Corporation Oligonucleótidos modificados para la inhibición de la telomerasa
US20120329858A1 (en) 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
PT3296312T (pt) 2004-07-02 2021-05-11 Geron Corp Síntese de monómeros nucleosídeos 3'-amino 5'-fosforamidite protegidos
WO2006113470A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2007127163A2 (en) 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
EP2101789B1 (en) 2006-10-30 2014-12-31 Geron Corporation Combined telomerase inhibitor and gemcitabine for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2011092201A5 (cg-RX-API-DMAC7.html)
JP2007504830A5 (cg-RX-API-DMAC7.html)
JP2016074736A5 (cg-RX-API-DMAC7.html)
JP2019511491A5 (cg-RX-API-DMAC7.html)
JP2019536464A5 (cg-RX-API-DMAC7.html)
JP2021113232A (ja) ペプチドオリゴヌクレオチドコンジュゲート
JP2013138681A5 (cg-RX-API-DMAC7.html)
JP2013510561A5 (cg-RX-API-DMAC7.html)
JP2008542285A5 (cg-RX-API-DMAC7.html)
EA201070030A1 (ru) Синтез и применение антиинвертированных фосфоротиоатных аналогов кэп-структуры матричной phk
JP2012500197A5 (cg-RX-API-DMAC7.html)
JP2019535839A (ja) 治療剤の送達のためのエクソソーム
JP2009536660A5 (cg-RX-API-DMAC7.html)
JP2012521201A5 (cg-RX-API-DMAC7.html)
JP2011246469A5 (cg-RX-API-DMAC7.html)
NZ588583A (en) Novel lipid formulations for nucleic acid delivery
JP2010513363A5 (cg-RX-API-DMAC7.html)
JP2009504783A5 (cg-RX-API-DMAC7.html)
JP2008533007A5 (cg-RX-API-DMAC7.html)
AR072858A1 (es) Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden
JP2007302689A5 (cg-RX-API-DMAC7.html)
JP2015512943A5 (cg-RX-API-DMAC7.html)
JP2018502956A5 (cg-RX-API-DMAC7.html)
BR122019023887B1 (pt) Ligantes de rig-i e composição farmacêutica
WO2011142798A3 (en) Methods of preparing targeted aptamer prodrugs